HealthQuill Neuroscience
Johnson & Johnson plans to acquire Israel’s privately-held V-Wave Ltd., for an upfront payment of $600 million, according to a statement from the US-based company.
Drugs Pharma

Johnson & Johnson ends late-stage trial of depression drug aticaprant

HQ Team March 7, 2025: Johnson & Johnson is discontinuing the Phase 3 VENTURA clinical trial of its experimental depression drug aticaprant after.

Read More
Johnson & Johnson will invest $2 billion to build a biologics manufacturing facility in Wilson, North Carolina, anticipating new products planned by the decade's end.
Drugs Health Pharma

J&J to build $2b facility in North Carolina to make future products

 HQ Team October 2, 2024: Johnson & Johnson will invest $2 billion to build a biologics manufacturing facility in Wilson, North Carolina, anticipating.

Read More